Applicant, as named in the Orange Book
Abbvie
Next listed expiry: Lumigan on 13 Jun 2027. 27 products with live protection, 33 without.
Products with listed protection
| Drug | Earliest generic entry |
|---|---|
| Lumigan NDA 022184 bimatoprost | 13 Jun 2027 patent |
| Acular Ls NDA 021528 ketorolac tromethamine | 24 Nov 2027 patent |
| Lastacaft NDA 022134 alcaftadine | 23 Dec 2027 patent, carve-out possible |
| Dalvance NDA 021883 dalbavancin hydrochloride | 23 May 2028 patent, carve-out possible |
| Canasa NDA 021252 mesalamine | 6 Jun 2028 patent |
| Acuvail NDA 022427 ketorolac tromethamine | 15 Aug 2029 patent |
| Savella NDA 022256 · 4 strengths milnacipran hydrochloride | 19 Sep 2029 patent, carve-out possible |
| Namzaric NDA 206439 · 4 strengths donepezil hydrochloride; memantine hydrochloride | 5 Dec 2029 patent, carve-out possible |
| Vraylar NDA 204370 · 6 strengths cariprazine hydrochloride | 17 Mar 2030 patent |
| Teflaro NDA 200327 · 2 strengths ceftaroline fosamil | 10 Feb 2031 patent |
| Kybella NDA 206333 deoxycholic acid | 17 Feb 2032 patent, carve-out possible |
| Fetzima NDA 204168 · 4 strengths levomilnacipran hydrochloride | 23 May 2032 patent |
| Avycaz NDA 206494 avibactam sodium; ceftazidime | 15 Jun 2032 patent |
| Emblaveo NDA 217906 avibactam sodium; aztreonam | 7 Feb 2033 exclusivity |
| Viberzi NDA 206940 · 2 strengths eluxadoline | 14 Mar 2033 patent |
| Venclexta NDA 208573 · 3 strengths venetoclax | 6 Sep 2033 patent, carve-out possible |
| Linzess NDA 202811 · 3 strengths linaclotide | 16 Feb 2034 patent |
| Durysta NDA 211911 bimatoprost | 31 Oct 2034 patent |
| Mavyret NDA 215110 glecaprevir; pibrentasvir | 5 Dec 2035 patent |
| Rinvoq Lq NDA 218347 upadacitinib | 17 Oct 2036 patent |
| Mavyret NDA 209394 glecaprevir; pibrentasvir | 24 Dec 2036 patent |
| Rinvoq NDA 211675 · 3 strengths upadacitinib | 9 Mar 2038 patent, carve-out possible |
| Vyalev NDA 216962 foscarbidopa; foslevodopa | 10 Jun 2040 patent, carve-out possible |
| Oriahnn (Copackaged) NDA 213388 elagolix sodium,estradiol,norethindrone acetate; elagolix sodium | 27 Aug 2040 patent, carve-out possible |
| Orilissa NDA 210450 · 2 strengths elagolix sodium | 27 Aug 2040 patent, carve-out possible |
| Qulipta NDA 215206 · 3 strengths atogepant | 29 Jul 2041 patent, carve-out possible |
| Ubrelvy NDA 211765 · 2 strengths ubrogepant | 22 Dec 2041 patent, carve-out possible |
Recent events
- Asacol Hd · Generic approved · ANDA 217736, Sciegen PharmsApproved 13 Oct 2026Detected 26 Oct 2026
- Tricor · Generic approved · ANDA 210379, Macleods PharmsApproved 21 Jan 2026Detected 25 Oct 2026
- Venclexta · First generic approved · ANDA 214733, Dr ReddysApproved 15 May 2026Detected 25 Oct 2026
- Venclexta · Generic approved · ANDA 214733, Dr ReddysApproved 15 May 2026Detected 25 Oct 2026
- Pred Forte · Generic approved · ANDA 212778, Upsher Smith LabsApproved 28 Sep 2026Detected 25 Oct 2026
- Viberzi · Generic approved · ANDA 213511, Aurobindo PharmaApproved 2 Jun 2026Detected 25 Oct 2026
- Kaletra · Generic approved · ANDA 214696, Micro LabsApproved 11 Dec 2025Detected 25 Oct 2026
- Dalvance · First generic approved · ANDA 219465, Teva Pharms IncApproved 23 Oct 2025Detected 25 Oct 2026
- Dalvance · Generic approved · ANDA 219465, Teva Pharms IncApproved 23 Oct 2025Detected 25 Oct 2026
- Dalvance · Generic approved · ANDA 218929, KindosApproved 26 Nov 2025Detected 25 Oct 2026
- Dalvance · Generic approved · ANDA 217591, Fresenius Kabi UsaApproved 10 Nov 2025Detected 25 Oct 2026
- Carafate · Generic approved · ANDA 216758, Novitium PharmaApproved 14 Oct 2026Detected 25 Oct 2026
- Savella · Generic approved · ANDA 207399, Strides PharmaApproved 15 Sep 2026Detected 25 Oct 2026
- Savella · Generic approved · ANDA 210944, Macleods PharmsApproved 15 Sep 2026Detected 25 Oct 2026
- Combigan · Generic approved · ANDA 217934, Saba Ilac SanayiveApproved 1 Jul 2026Detected 25 Oct 2026
- Fml Forte · Generic approved · ANDA 218819, SandozApproved 12 Feb 2026Detected 25 Oct 2026
- Namzaric · Generic approved · ANDA 208359, Strides Pharma IntlApproved 13 Oct 2026Detected 25 Oct 2026
- Rectiv · Generic approved · ANDA 214565, Padagis IsraelApproved 6 Jul 2026Detected 25 Oct 2026
- Linzess · Generic approved · ANDA 211255, Actavis Labs FlApproved 24 Sep 2026Detected 25 Oct 2026
- Rectiv · Generic approved · ANDA 218756, AmvikaApproved 18 Dec 2025Detected 25 Oct 2026
- Lexapro · Generic approved · ANDA 091655, Micro LabsApproved 22 Apr 2026Detected 25 Oct 2026
- Ubrelvy · Generic tentatively approved · ANDA 219218, Msn Laboratories Private LimitedTentative approval 24 Jun 2026Detected 25 Oct 2026
- Combigan · Generic approved · ANDA 219166, GlandApproved 11 Jun 2026Detected 25 Oct 2026
- Ubrelvy · Generic tentatively approved · ANDA 218662, Zydus Pharmaceuticals (Usa) Inc.Tentative approval 14 May 2026Detected 25 Oct 2026
- Dalvance · Generic approved · ANDA 218602, Long Grove PharmsApproved 26 Feb 2026Detected 25 Oct 2026
- Dalvance · Generic approved · ANDA 219604, Be PharmsApproved 4 Jun 2026Detected 25 Oct 2026
- Vraylar · Generic approved · ANDA 213982, Aurobindo Pharma LtdApproved 16 Dec 2025Detected 25 Oct 2026
- Lumigan · Generic approved · ANDA 217289, AmnealApproved 22 Sep 2025Detected 25 Oct 2026
- Carafate · Generic approved · ANDA 212141, Glenmark Pharms LtdApproved 5 Jan 2026Detected 25 Oct 2026
- Mavyret · Exclusivity expires within 90 days PEDExclusivity expires 30 Oct 2026Detected 24 Oct 2026
- Byvalson · Enters 12-month window basis: patent, carve-out possibleListed date 4 Oct 2027Detected 24 Oct 2026
- Lumigan · Enters 12-month window basis: patentListed date 13 Jun 2027Detected 24 Oct 2026
Products without listed protection (33)
| Drug | Earliest generic entry |
|---|---|
| Acular NDA 019700 ketorolac tromethamine | open now no listed protection |
| Alphagan P NDA 021262 brimonidine tartrate | open now no listed protection |
| Alphagan P NDA 021770 brimonidine tartrate | open now no listed protection |
| Carafate NDA 018333 sucralfate | open now no listed protection |
| Celexa NDA 020822 · 3 strengths citalopram hydrobromide | open now no listed protection |
| Combigan NDA 021398 brimonidine tartrate; timolol maleate | open now no listed protection |
| Crinone NDA 020701 progesterone | open now no listed protection |
| Depakote NDA 019680 divalproex sodium | open now no listed protection |
| Depakote NDA 018723 · 3 strengths divalproex sodium | open now no listed protection |
| Depakote Er NDA 021168 · 2 strengths divalproex sodium | open now no listed protection |
| Duopa NDA 203952 carbidopa; levodopa | open now no listed protection |
| Fml NDA 016851 fluorometholone | open now no listed protection |
| Fml Forte NDA 019216 fluorometholone | open now no listed protection |
| Juvmo NDA 220415 · 3 strengths tavapadon | open now no listed protection |
| Juvmo (Copackaged) NDA 220415 tavapadon | open now no listed protection |
| Kaletra NDA 021251 lopinavir; ritonavir | open now no listed protection |
| Kaletra NDA 021906 · 2 strengths lopinavir; ritonavir | open now no listed protection |
| Latisse NDA 022369 bimatoprost | open now no listed protection |
| Lexapro NDA 021323 · 3 strengths escitalopram oxalate | open now no listed protection |
| Norvir NDA 209512 ritonavir | open now no listed protection |
| Norvir NDA 022417 ritonavir | open now no listed protection |
| Oxytrol For Women NDA 202211 oxybutynin | open now no listed protection |
| Ozurdex NDA 022315 dexamethasone | open now no listed protection |
| Pred Forte NDA 017011 prednisolone acetate | open now no listed protection |
| Pred Mild NDA 017100 prednisolone acetate | open now no listed protection |
| Restasis NDA 050790 cyclosporine | open now no listed protection |
| Restasis Multidose NDA 050790 cyclosporine | open now no listed protection |
| Saphris NDA 022117 · 3 strengths asenapine maleate | open now no listed protection |
| Synthroid NDA 021402 · 12 strengths levothyroxine sodium | open now no listed protection |
| Ultane NDA 020478 sevoflurane | open now no listed protection |
| Viibryd NDA 022567 · 3 strengths vilazodone hydrochloride | open now no listed protection |
| Zemplar NDA 020819 · 3 strengths paricalcitol | open now no listed protection |
| Zymaxid NDA 022548 gatifloxacin | open now no listed protection |